Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 1747–1753 | Cite as

Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma

  • Liang Wang
  • Jing-hua Wang
  • Zhi-jun Wu-Xiao
  • Zhong-jun Xia
  • Hui-qiang Huang
  • Yue Lu
Research Article

Abstract

Recently, absolute lymphocyte count (ALC) at diagnosis, as a surrogate marker of host immunity, has been reported to be a prognostic factor for clinical outcomes in extranodal NK/T cell lymphoma (ENKTL). In this retrospective study, we set out to investigate whether ALC at the time of confirmed relapse or at last follow-up is a marker for relapse after chemoradiotherapy in 84 patients with stage I/II ENKTL. Receiver operating characteristics (ROC) curve and area under the curve (AUC) analysis showed that ALC at follow-up was a significant marker for relapse (AUC = 0.883, P < 0.001). Using 1.215 × 109/L as the optimal cutoff value of ALC, 44 patients (52.4 %) were in lower ALC group and 40 patients (47.6 %) were in higher ALC group. The sensitivity and specificity for ALC at the time of confirmed relapse or at last follow-up was 94.1 and 76.0 %, respectively. The relative risk of relapse with an ALC < 1.215 × 109/L was 14.5. The positive predictive value with an ALC < 1.215 × 109/L was 72.7 %, and the negative predictive value with an ALC ≥ 1.215 × 109/L was 95.0 %. The 4-year cumulative incidence rate for an ALC < 1.215 × 109/L was 73.2 % compared with 3.2 % for an ALC ≥ 1.215 × 109/L (P < 0.001). In a multivariate regression analysis, ALC at the time of confirmed relapse or last follow-up remained to be a significant factor for relapse (P < 0.001). In conclusion, lymphopenia observed during routine follow-up can predict relapse in patients with ENKTL, which needs further validation in prospective trials.

Keywords

Absolute lymphocyte count Lymphopenia Relapse Extranodal NK/T cell lymphoma 

Notes

Acknowledgments

We thank all of the physicians at Sun Yat-sen University Cancer Center for allowing us to include their patients. We also appreciate the cooperation of all the pathologists at Sun Yat-sen University Cancer Center for their support.

Financial support

This work received grant support from National Natural Science Foundation of China (contract/grant number: 81400159), Medical Research Foundation of Guangdong Province (grant number: B2014158), Young Teachers’ Cultivation Project of Sun Yat-sen University (No. 12ykpy54), and Outstanding Young Talents Project of Sun Yat-sen University Cancer Center (No. 04190101#).

Conflicts of interest

None

References

  1. 1.
    Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15(8):2905–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–600.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Jaccard A, Gachard N, Marin B, et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang Y, Wei Y, Wang X, et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of l-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006;24:28–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96(5):617–23.CrossRefPubMedGoogle Scholar
  11. 11.
    National Comprehensive Cancer Network (NCCN). Extranodal NK/T-cell lymphoma, nasal type. Pract Guidel Oncol. 2013;1.Google Scholar
  12. 12.
    National Comprehensive Cancer Network (NCCN). Diffuse large B-cell lymphoma. Practice Guidel Oncol. 2013;1.Google Scholar
  13. 13.
    Schoulten HC. Response evaluation and long term follow-up. Ann Oncol. 2007;18 Suppl 1:i33–6.CrossRefGoogle Scholar
  14. 14.
    Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, et al. Absolute lymphocyte count is novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011;22(1):149–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:745–51.CrossRefGoogle Scholar
  16. 16.
    Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010;24(7):1343–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285–8.Google Scholar
  18. 18.
    Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in thetreatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31(3):860.CrossRefPubMedGoogle Scholar
  19. 19.
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefPubMedGoogle Scholar
  20. 20.
    Thompson CA, Maurer MJ, Ghesquieres H, et al. Utility of post-therapy surveillance scans in DLBCL. J Clin Oncol. 2013;(suppl; abstr 8504).Google Scholar
  21. 21.
    Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Mar 19.Google Scholar
  25. 25.
    Huang JJ, Li YJ, Xia Y, et al. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer. 2013;13:222.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Habermann TM. Posttransplant lymphoproliferative disorders. Cancer Treat Res. 2008;142:273–92.PubMedGoogle Scholar
  27. 27.
    Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y. Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med Oncol. 2013;30(4):723.CrossRefPubMedGoogle Scholar
  28. 28.
    Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169–76.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Liang Wang
    • 1
    • 2
  • Jing-hua Wang
    • 1
  • Zhi-jun Wu-Xiao
    • 3
  • Zhong-jun Xia
    • 1
    • 2
  • Hui-qiang Huang
    • 2
    • 4
  • Yue Lu
    • 1
    • 2
  1. 1.Department of Hematological Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  2. 2.State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouPeople’s Republic of China
  3. 3.Department of Hematology/OncologyThe Affiliated Hospital of Hainan Medical CollegeHaikouPeople’s Republic of China
  4. 4.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China

Personalised recommendations